PT  - JOURNAL ARTICLE
AU  - Padoan, Andrea
AU  - Bonfante, Francesco
AU  - Cosma, Chiara
AU  - Chiara, Costanza Di
AU  - Sciacovelli, Laura
AU  - Pagliari, Matteo
AU  - Bortolami, Alessio
AU  - Costenaro, Paola
AU  - Musso, Giulia
AU  - Basso, Daniela
AU  - Giaquinto, Carlo
AU  - Plebani, Mario
TI  - Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers
AID  - 10.1101/2021.03.10.21253260
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.10.21253260
4099  - http://medrxiv.org/content/early/2021/03/12/2021.03.10.21253260.short
4100  - http://medrxiv.org/content/early/2021/03/12/2021.03.10.21253260.full
AB  - Background SARS-CoV-2 serology presents an important role in understanding the virus epidemiology, in vaccine prioritization strategies and in convalescent plasma therapy. Immunoassays performances have to be accurately evaluated and correlated with neutralizing antibodies to be used as a surrogate measure of neutralizing activity. We investigate the analytical and clinical performance of a SARS-CoV-2 RBD IgG assay, automated on a high throughput platform, and the correlation of the antibodies (Ab) levels with the plaque reduction neutralization (PRNT50) Ab titers.Methods A series of 546 samples were evaluated by SARS-CoV-2 RBD IgG assay (Snibe diagnostics), including 171 negative and 168 positive SARS-CoV-2 subjects and a further group of 207 subjects of the COVID-19 family clusters follow-up cohort.Results Assay precision was acceptable at low and medium levels; linearity was excellent in all the measurement range. Considering specimens collected after 14 days post symptoms onset, overall sensitivity and specificity were 99.0% and 92.5%, respectively. A total of 281 leftover samples results of the PRNT50 test were available. An elevated correlation was obtained between the SARS-CoV-2 RBD IgG assay and the PRNT50 titer at univariate (rho = 0.689) and multivariate (rho = 0.712) analyses.Conclusions SARS-CoV-2 S-RBD IgG assay achieves elevated analytical and clinical performances, and a strong correlation with sera neutralization activity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol (number 23307) was approved by the Ethics Committee of the University-Hospital, Padova. All the patients were informed of the study and voluntarily agreed to participate, providing a written consentAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request